Skip to content

Effect of esmolamine on depression in patients with Parkinson's disease undergoing non-craniocerebral surgery

Effect of esmolamine on depression in patients with Parkinson's disease undergoing non-craniocerebral surgery

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500098063
Enrollment
Unknown
Registered
2025-03-03
Start date
2024-11-05
Completion date
Unknown
Last updated
2025-03-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson's disease

Interventions

Esmolamine group (group ES).:In ES group, 0.25mg/ Ketamine was given at the time of anesthesia induction and 0.125mg/ (kg ·h) was pumped to 30 minutes before the end of operation.
Control group (group C):Group C was injected with saline at the same time.

Sponsors

Yancheng Third People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
60 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1. Age 60-90; 2. Regardless of gender; 3. American Association of Anesthesiologists (American Society of Anesthesiologists,ASA) rating: grade I ~ III; 4. Diagnosis of Parkinson's disease; 5. Non-craniocerebral surgery under general anesthesia; 6. Volunteer to participate in the trial and sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1. With severe depression or other mental illness, it is impossible to accurately assess the state of depression (oral antidepressants); 2. Severe heart, liver or kidney disease before operation; 3. Body mass index (BMI) > 35 kg/m^2; 4. Those who have communication difficulties or are unable to cooperate; 5. Uncontrolled hypertension (baseline value-gt;180/100mmHg); 6. Allergic or taboo use of esmolamine (history of glaucoma or hyperthyroidism).

Design outcomes

Primary

MeasureTime frame
Self-Rating Depression Scale(SDS) Score;

Secondary

MeasureTime frame
5-HT;NA;TNF-a;IL-6;

Countries

China

Contacts

Public ContactWang Shu

Yancheng Third People's Hospital

735524111@qq.com+86 152 6198 0226

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Apr 17, 2026